Summary
Global Markets Direct’s, ‘Rubella - Pipeline Review, H1 2016’, provides an overview of the Rubella pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Rubella, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rubella and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Rubella
- The report reviews pipeline therapeutics for Rubella by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Rubella therapeutics and enlists all their major and minor projects
- The report assesses Rubella therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Rubella
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Rubella
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Rubella pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Beijing Minhai Biotechnology Co., Ltd
Beijing Tiantan Biological Products Co., Ltd.
Biological E. Limited
China National Pharmaceutical Group Corporation
Daiichi Sankyo Company, Limited
GlaxoSmithKline Plc
Prometheon Pharma, LLC
Sinovac Biotech Ltd.
Zydus Cadila Healthcare Limited
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Rubella Overview 6
Therapeutics Development 7
Pipeline Products for Rubella - Overview 7
Pipeline Products for Rubella - Comparative Analysis 8
Rubella - Therapeutics under Development by Companies 9
Rubella - Therapeutics under Investigation by Universities/Institutes 10
Rubella - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Rubella - Products under Development by Companies 14
Rubella - Products under Investigation by Universities/Institutes 15
Rubella - Companies Involved in Therapeutics Development 16
Beijing Minhai Biotechnology Co., Ltd 16
Beijing Tiantan Biological Products Co., Ltd. 17
Biological E. Limited 18
China National Pharmaceutical Group Corporation 19
Daiichi Sankyo Company, Limited 20
GlaxoSmithKline Plc 21
Prometheon Pharma, LLC 22
Sinovac Biotech Ltd. 23
Zydus Cadila Healthcare Limited 24
Rubella - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Combination Products 26
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
(measles + mumps + rubella + varicella) (tetravalent) vaccine - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
(measles + mumps + rubella + varicella) vaccine - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
(measles + mumps + rubella) vaccine - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
(measles + mumps + rubella) vaccine - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
(measles + mumps + rubella) vaccine - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
(measles + rubella + varicella) vaccine - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
(measles + rubella) vaccine - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
(measles + rubella) vaccine - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
(measles [strain Schwarz] + mumps [strain RIT 4385] + rubella [strain Wistar RA 27/3]) vaccine - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
measles + mumps + rubella + varicella vaccine - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
VN-0102 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Rubella - Recent Pipeline Updates 42
Rubella - Dormant Projects 43
Appendix 44
Methodology 44
Coverage 44
Secondary Research 44
Primary Research 44
Expert Panel Validation 44
Contact Us 44
Disclaimer 45
List of Tables
Number of Products under Development for Rubella, H1 2016 7
Number of Products under Development for Rubella - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Number of Products under Investigation by Universities/Institutes, H1 2016 10
Comparative Analysis by Late Stage Development, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 12
Comparative Analysis by Early Stage Development, H1 2016 13
Products under Development by Companies, H1 2016 14
Products under Investigation by Universities/Institutes, H1 2016 15
Rubella - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2016 16
Rubella - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H1 2016 17
Rubella - Pipeline by Biological E. Limited, H1 2016 18
Rubella - Pipeline by China National Pharmaceutical Group Corporation, H1 2016 19
Rubella - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 20
Rubella - Pipeline by GlaxoSmithKline Plc, H1 2016 21
Rubella - Pipeline by Prometheon Pharma, LLC, H1 2016 22
Rubella - Pipeline by Sinovac Biotech Ltd., H1 2016 23
Rubella - Pipeline by Zydus Cadila Healthcare Limited, H1 2016 24
Assessment by Monotherapy Products, H1 2016 25
Assessment by Combination Products, H1 2016 26
Number of Products by Stage and Route of Administration, H1 2016 28
Number of Products by Stage and Molecule Type, H1 2016 30
Rubella Therapeutics - Recent Pipeline Updates, H1 2016 42
Rubella - Dormant Projects, H1 2016 43
List of Figures
Number of Products under Development for Rubella, H1 2016 7
Number of Products under Development for Rubella - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 12
Comparative Analysis by Early Stage Products, H1 2016 13
Assessment by Combination Products, H1 2016 26
Number of Products by Routes of Administration, H1 2016 27
Number of Products by Stage and Routes of Administration, H1 2016 27
Number of Products by Molecule Types, H1 2016 29
Number of Products by Stage and Molecule Types, H1 2016 29
